- Business Wire•2 days ago
Enanta Announces Eight Weeks of Treatment with AbbVie’s Investigational, Pan-Genotypic, Ribavirin-Free HCV Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates in Challenging-to-Treat Genotype 3 Chronic HCV Patients
Enanta Pharmaceuticals, Inc. , a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported that AbbVie announced high SVR rates were achieved with 8 weeks of treatment with its investigational, once daily, ribavirin-free, pan-genotypic regimen of glecaprevir/pibrentasvir in patients with challenging-to-treat ...
- PR Newswire•3 days ago
Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR(12) Rates in Challenging to Treat Genotype 3 Chronic Hepatitis C
AMSTERDAM, April 21, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced high SVR 12 rates were achieved with 8 weeks of treatment with its investigational, once-daily, ...
- Business Wire•3 days ago
Enanta Announces 99 Percent SVR12 Rate in Chronic HCV Patients with Compensated Cirrhosis Treated with AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P)
Enanta Pharmaceuticals, Inc. , a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that 99 percent of chronic hepatitis C virus infected patients with genotype 1, 2, 4, 5 or 6 and compensated cirrhosis achieved sustained virologic response at 12 weeks post-treatment with AbbVie’s investigational, ...
ENTA : Summary for Enanta Pharmaceuticals, Inc. - Yahoo Finance
Enanta Pharmaceuticals, Inc. (ENTA)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||18.13 x 100|
|Ask||31.10 x 900|
|Day's Range||30.50 - 30.93|
|52 Week Range||20.79 - 37.31|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-61.26|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|